Gastro Esophageal Junction Cancer Recruiting Phase 2 Trials for Anlotinib (DB11885)

Also known as: Gastroesophageal-junction Cancer / Gastroesophageal Junction Cancer / Gastro-oesophageal Junction Cancer / Gastro-esophageal Junction Cancer / Gastrooesophageal junction cancer / Carcinoma of oesophagus NOS / Carcinoma of oesophagus / Carcinoma of esophagus (disorder) / Carcinoma of esophagus / Oesophageal carcinoma NOS / Oesophageal carcinoma / Esophageal carcinoma NOS / Esophageal carcinoma / Primary malignant neoplasm of esophagus (disorder)

DBCOND0106887 (Gastro Esophageal Junction Cancer)Recruiting2 IdentifierTitlePurposeDrugs
NCT04278222Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)Treatment